Meeting the Renewed Demand for Microbial Protein Production

January 28, 2022 PAO-01-22-R250-07

As part of our Road to 50 States campaign, Ramon Biosca, Head of Operations for the CDMO business at the Grifols Diagnostics Solutions, sits down with Nigel to discuss the impacts of the COVID-19 pandemic and the renaissance in demand for microbial cell culture.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Grifols Recombinant Protein CDMO

Grifols Recombinant Protein CDMO provides CDMO services for bulk recombinant proteins produced by microbial and mammalian expression systems for use in diagnostics, therapeutics and vaccines.  Based in the San Francisco Bay Area, they have three decades of process development and GMP manufacturing experience, and they support long-term relationships through expertise, quality, and reliability.

Q: